The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Johanna Abelsson(NU Hospital Group), Marjut Kauppila(Turku University Hospital), Gunnar Birgegård(Uppsala University Hospital), Kari Remes(Turku University Hospital), Peter Johansson(Linköping University), Christer Malm, Björn Andréasson(NU Hospital Group), Lorentz Brinch(Oslo University Hospital), Mats Merup(Karolinska University Hospital), Maria Liljeholm(University Hospital of Umeå), Mats Brune(Sahlgrenska University Hospital), Stig Lenhoff(Lund University), Ole Weis-Bjerrum(University of Copenhagen), Lars L. Vindeløv(University of Copenhagen)

Bone Marrow Transplantation

May 9, 2011

10.1038/bmt.2011.91

Cited by 70

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

|Bone Marrow Transplantation|2009|385

Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation

|Blood|1996|363

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

|JAMA|2011|323